Most studies investigating GLP-1 receptors, whether as a drug for type 2 diabetes or obesity, have shown that the most common adverse events were gastrointestinal (GI) events (Dungan et al. 2014; Pratley et al. 2014; Rosenstock et al. 2013), which is consistent with our findings. This evidence concerns the gene GLP1R and obesity disorder.